European consensus proposal for immunoglobulin therapies

European Journal of Immunology

Volumn 44, Issue 8, 2014, Pages 2207-2214

  Sewell, W A Carrock ^a   Kerr, Jacqueline ^b   Behr Gross, Marie Emmanuelle ^c,e   Peter, Hans Hartmut ^d   Drabwell, Jose ^f   Eibl, Martha ^g   Golding, Basil ^h   Kuijpers, Taco ⁱ   Quinti, Isabella ^j   van Schaik, Ivo N ⁱ   Sediva, Anna ^k   Seppänen, Mikko ^l   Späth, Peter J ^m  

^a UNIVERSITY OF HULL   (United Kingdom)

^b PAUL EHRLICH INSTITUT   (Germany)

^c European Network of National Information Centers   (France)

^d Molecular Epidemiology   (Germany)

^e EDQM Laboratory   (France)

^f IPOPI Board   (United Kingdom)

^g Immunologische Tagesklinik   (Austria)

^h CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

ⁱ ACADEMIC MEDICAL CENTER   (Netherlands)

^j SAPIENZA UNIVERSITY OF ROME   (Italy)

^k UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^l HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^m UNIVERSITY OF BERN   (Switzerland)

more..

Author keywords

Antibodies; Immunodeficiencies; Immunoglobulins; Immunopathology; Immunotherapy

Indexed keywords

DEXAMETHASONE; IMMUNOGLOBULIN G; RITUXIMAB;

ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); CONSENSUS; DRUG SAFETY; EUROPE; HEALTH CARE ACCESS; HEALTH CARE NEED; HISTORY OF MEDICINE; HUMAN; IMMUNE DEFICIENCY; IMMUNOMODULATION; IMMUNOTHERAPY; NONHUMAN; OPTIMAL DRUG DOSE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SUBSTITUTION THERAPY; WORLD HEALTH ORGANIZATION;

ANTIBODIES; IMMUNODEFICIENCIES; IMMUNOGLOBULINS; IMMUNOPATHOLOGY; IMMUNOTHERAPY;

CONSENSUS; EUROPE; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULINS;

EID: 84906087039     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201444700     Document Type: Article

References (78)

1. O'Mahony, B. et al., Haemophilia 2013. 19: 239-247.
2. Seitz, R. et al., Kreuth III Proceedings: optimal use of clotting factors and immunoglobulins. http://www.edqm.eu/medias/fichiers/full_proceedings_kreuth_iii.pdf, 2013.
3. Edsall, J. T., Edwin Joseph Cohn 1892-1953 A Biographical Memoir, National Academy of Sciences, http://www.nasonline.org/publications/biographicalmemoirs/memoir-pdfs/cohn-edwin-j.pdf, 1961.
4. Robert, P., Pharmaceuticals Policy and Law. 2009. 11: 359-367.
5. Stonebraker, J. S. et al., J. Clin. Immunol. 2014. 34: 233-244.
6. Imbach, P., Swiss Med. Wkly. 2012. 142: w13593.
7. Orange, J. S. et al., J. Allergy Clin. Immunol. 2006. 117(Suppl. 4): 525-553.
8. Hartung, H. P. et al., Clin. Exp. Immunol. 2009. 158(Suppl. 1): 23-33.
9. Kaveri, S., Curr. Opin. Allergy Clin. Immunol. 2013. 13(Suppl. 2): 51-78.
10. Gathmann, B. et al., Clin. Exp. Immunol. 2012. 167: 479-491.
11. Delforge, M. et al., Acta Clin. Belg. 2011. 66: 1-15.
12. Patwa, H. S. et al., Neurology 2012. 78: 1009-1015.
13. Schwab, I. and Nimmerjahn, F., Nat. Rev. Immunol. 2013.13: 176-189.
14. Fokkink, W. J. et al., J. Proteome Res. 2014. 13: 1722-17130.
15. Leontyev, D. et al., Blood 2012. 119: 5261-5264.
16. Seok, J. et al., Proc. Natl. Acad. Sci. USA 2013. 110: 3507-3512s.
17. Käsermann, F. et al., PLoS One 2012. 7: e37243.
18. Buchacher, A. and Iberer, G., Biotechnol. J. 2006. 1: 148-163.
19. Radosevich, M. and Burnouf, T., Vox Sang. 2010. 98: 12-28.
20. Edgeworth, J. A. et al., Lancet 2011. 377: 487-493.
21. Menis, M. et al., Am. J. Hematol. 2013. 88: 1035-1040.
22. Thorpe, S. J. et al., Vox Sang. 2003. 85: 80-84.
23. Desborough, M. J. et al., Transfus. Med. 2013. doi: 10.1111/tme.12083.
24. Thorpe, S. J. et al., Vox Sang. 2009. 97: 160-168.
25. Khan, S. et al., Drug Metab. Lett. 2011. 5: 132-136.
26. Orange, J. S. et al., Clin. Immunol. 2010. 137: 21-30.
27. Orange, J. S. et al., Clin. Exp. Immunol. 2012. 169: 172-181.
28. Bonagura, V. R., Ann. Allergy Asthma Immunol. 2013. 111(Suppl. 6): S10-S13.
29. Gregersen, S. et al., Ann. Allergy Asthma Immunol. 2010. 104: 503-510.
30. Quinti, I. et al., J. Clin. Immunol. 2011. 31: 315-322.
31. Gouilleux-Gruart, V. et al., Clin. Exp. Immunol. 2013. 171: 186-194.
32. Chapel, H. et al., Allergy Clin. Immunol. 2012. 130: 1197-1198.
33. Blanchette, V. et al., Lancet 1994. 344: 703-707.
34. Newburger, J. W. et al., N. Engl. J. Med. 1991. 324: 1633-1639.
35. Eleftheriou, D. et al., Arch. Dis. Child. 2014. 99: 74-83.
36. Eftimov, F. et al., Cochrane Database Syst. Rev. 2013. 12: CD001797.
37. Hughes, R. A. et al., Lancet Neurol. 2008. 7: 136-144.
38. Lee, D. H. et al., Muscle Nerve 2008. 37: 406-409.
39. Markvardsen, L. H. et al., Eur. J. Neurol. 2013. 20: 836-842.
40. Bright, R. J. et al., BMC Neurol. 2014. 14: 26-35.
41. Blackhouse, G. et al., Cost Eff. Resour. Alloc. 2010, 8: 14-23
42. Robinson, P. et al., Transfus. Med. Rev. 2007. 21(Suppl. 1): S3-S8.
43. Shehata, N. et al., Transfus. Med. Rev. 2010. 24(Suppl. 1): S28-S50.
44. National Blood Authority, Australia. Criteria for the clinical use of intravenous immunoglobulin in Australia 2012, http://www.blood.gov.au/sites/default/files/documents/nba-ivig-criteria-for-use-2nd-edition.pdf.
45. Wimperis, J. et al., Clinical guideline for immunoglobuline use. 2nd edition. Department of Health, London, UK, 2011.
46. Demand Management Plan for Immunoglobulin use. Crown Copyright, Department of Health, London, UK, (2011).
47. Shehata, N. et al., Transfus. Med. Rev. 2010. 24(Suppl. 1): S7-S27.
48. Enk, A. et al., J. Dtsch. Dermatol. Ges. 2009. 7: 806-812. Update: http://www.euroderm.org/images/stories/guidelines/guideline_on_ivig-update2011-a.pdf.
49. Orange, J. S. et al., J. Clin. Immunol. 2013. 33: 1033-1036.
50. Gajdos, P. et al., Cochrane Database Syst. Rev. 2012. 12: CD002277.
51. Makowsky, R. et al., Pharmacogenet. Genomics 2013. 23: 455-462.
52. Ogata, S. et al., PLoS One 2013. 8: e81448.
53. Wasserman, R. L. et al., J. Allergy Clin. Immunol. 2012. 130: 951-957.
54. Shapiro, R. S., Ann. Allergy Asthma Immunol. 2013. 111: 51-55.
55. Kumar, A. et al., Int. Arch. Allergy Immunol. 2006. 140: 185-198.
56. Mouthon, L. et al., Curr. Opin. Allergy Clin. Immunol. 2013. 13(Suppl. 2): 51-78.
57. Frauger, E. et al., Fundam. Clin. Pharmacol. 2011. 25: 753-761.
58. Raanani, P. et al., Leuk. Lymphoma 2009. 50: 764-772.
59. Boughton, B. J. et al., Clin. Lab. Haematol. 1995. 17: 75-80.
60. Raanani, P. et al., J. Clin. Oncol. 2009. 27: 770-781.
61. Sinisalo, M. et al., Vaccine 2007. 26: 82-87.
62. Marchalonis, J. J. et al., Proc. Natl. Acad. Sci. USA 1992. 89: 3325-3329.
63. Rossi, F. et al., Immunol. Rev. 1989. 110: 135-149.
64. Bouhlal, H. et al., J. Clin. Immunol. 2014. 34(Suppl. 1): 4-11.
65. Ravindranath, M. H. et al., Blood 2013. 121: 2013-2028.
66. Séïté, J. F. et al., J. Allergy Clin. Immunol. 2014. 133: 181-188.
67. Zhu, D. et al., Clin. Exp. Immunol. 2014. doi: 10.1111/cei.12307
68. De Groot, A. S. et al., Clin. Dev. Immunol. 2013. 2013: 493138.
69. Othy, S. et al., J. Immunol. 2013. 190: 4535-4541.
70. Durandy, A. et al., Clin. Exp. Immunol. 2009. 158(Suppl. 1): 2-13.
71. Kwekkeboom, J. Adv. Exp. Med. Biol. 2012. 750: 133-144.
72. Trinath, J. et al., J. Allergy Clin. Immunol. 2013. 131: 1255-1257.
73. Maddur, M. S. et al., J. Clin. Immunol. 2013. 33(Suppl. 1): S62-S66.
74. von Gunten, S. et al., J. Clin. Immunol. 2010. 30(Suppl. 1): S24-S30.
75. von Gunten, S. et al., Nat. Rev. Immunol. 2014. 14: 349.
76. Andersen, J. T. and Sandlie, I., Drug Metab. Pharmacokinet. 2009. 24: 318-332.
77. van der Neut Kolfschoten, M. et al., Science 2007. 317: 1554-1557.
78. Nirula, A. et al., Curr. Opin. Rheumatol. 2011. 23: 119-124.